FDG PET in Prostate Cancer

被引：35

作者：

Jadvar, Hossein ^{[1
]}

机构：

[1] Univ Southern Calif, Keck Sch Med, Dept Radiol, Div Nucl Med, 2250 Alcazar St,CSC 102, Los Angeles, CA 90033 USA

来源：

PET CLINICS | 2009年 / 4卷 / 02期

基金：

美国国家卫生研究院;

关键词：

PET; CT; FDG; Prostate; Cancer;

D O I：

10.1016/j.cpet.2009.05.002

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

The role of positron emission tomography (PET) with [F-18]-fluorodeoxyglucose (FDG) for the imaging evaluation of patients who have cancer has expanded rapidly worldwide. The exact clinical use of PET and PET-computed tomography in prostate cancer is currently being explored. The recent publications summarizing the NOPR findings showed that prostate cancer was one of the most common cancers with patient enrollment. This article first reviews the limited available data on the molecular biology basis of FDG accumulation in prostate cancer, and then briefly reviews the current clinical experience with the use of PET with FDG in the imaging evaluation of prostate cancer.

引用

页码：155 / +

页数：8

共 53 条

[1]

Agus DB, 1998, CANCER RES, V58, P3009

[2] Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer [J].